applepharmaceutical@gmail.com

CATEGORIES

hepatitis-image
hiv-image
cancer-image

cancermed

CANCER CELLS

velpaclear

 11-Mon--0001     By admin

news

Both drugs sofosbuvir 400mg and Velpatasvir 100mg is essential for blocking two proteins multiplication of hepatitis C virus. Sofosbuvir stops the action of an enzyme called "NS5B RNA-dependent RNA polymerase”and reduce amount of hepatitis C virus present in the body. Velpatasvir binds a protein "NS5A" and blocks the virus multiplication spreading inside the body ABSORPTION: oral administration of Velpaclear, the peak plasma concentration of Sofosbuvir approx 0.5-1 hour after the dose and Velpatasvir occurs 3 hrs after the dose. In healthy adult and infected adults , have plasma concentration and AUC of Velpatasvir are 42 and 37% lower. Administration of food with moderate fat or high fat meal both drugs (Sofosbuvir/Velpatasvir) increases the exposure Sofosbuvir (60 or 305 fat) and Velpatasvir (34 or21%) respectively DISTRIBUTION: Plasma protein binding is 61-65% for Sofosbuvir and >99.5% is Velpatasvir METABOLISM: Sofosbuvir metabolized in liver by GS-461203 and desphosphorylation leads to formation of GS-331007. Velpatasvir: Metabolized by CYP2B6,2C8 and 3A4. ELIMINATION: Sofosbuvir major route is renal clearance via urine 80% and14% in feces and 2.5% in expired air. Velepatasvir major route is biliary excretion and dose eliminated 94% in feces and 0.4% in urine and half life is Sofosbuvir 0.5hours, its GS-331007 is 25 hours and Velpatasvir is 15 hours.